Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group

Gynecologic Oncology
C A BrewerParviz Hanjani

Abstract

To evaluate the safety and efficacy of cisplatin plus gemcitabine in persistent or recurrent platinum-resistant ovarian and primary peritoneal cancer. Eligible, consenting subjects with measurable disease and one prior platinum-based regimen, but no prior gemcitabine, were to receive intravenous cisplatin followed by gemcitabine on days 1 and 8 every 28 days. Between December 2000 and March 2003, 59 patients were enrolled from 24 institutions; two were ineligible. During the first stage of accrual, 27 subjects received cisplatin 30 mg/m2 and gemcitabine 750 mg/m2. In the second stage, gemcitabine was reduced to 600 mg/m2 because of hematologic toxicity at the higher dose. There were 4 complete and 5 partial responses for an overall response rate of 16% (9/57). Thirty-one women (54%) had stable disease. Median time to progression was 5.4 months. Overall survival was 14.9+ months. Grade 4 toxicities were hematologic, except one cutaneous reaction. Cisplatin plus gemcitabine, in the doses and schedule employed, has modest activity in this patient population.

References

Oct 7, 1992·Journal of the National Cancer Institute·M DabholkarE Reed
Aug 28, 2002·Journal of the European Academy of Dermatology and Venereology : JEADV·I KukuI Aydogdu
Sep 27, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Roland B WalterBernhard C Pestalozzi
Mar 22, 2003·Gynecologic Oncology·Giuseppe D'AgostinoIgnace Vergote
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gordon J S Rustin
Sep 19, 2003·Gynecologic Oncology·Maurie MarkmanJerome Belinson

❮ Previous
Next ❯

Citations

Jul 28, 2013·International Journal of Clinical Oncology·Yui TomitaKumi Shimamoto
May 1, 2007·Women's Health·Fadi Abushahin, Peter G Rose
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David S MillerCecelia H Boardman
Jul 21, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S B KayeA Poveda
Feb 6, 2013·Nature Reviews. Clinical Oncology·Robert L ColemanThomas J Herzog
Oct 17, 2006·Current Oncology Reports·Thomas J Herzog
Sep 8, 2010·Expert Opinion on Investigational Drugs·Koji MatsuoAnil K Sood
Apr 14, 2009·Gynecologic Oncology·David M GershensonJohn J Kavanagh
Oct 3, 2008·Gynecologic Oncology·Debra L RichardsonLarry J Copeland
Apr 10, 2014·Journal of Ovarian Research·Hiroshi KawaguchiMasahide Ohmichi
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Susan C Modesitt, Amir A Jazaeri
Nov 11, 2008·American Journal of Obstetrics and Gynecology·Shawna L Bull PhelpsJayanthi S Lea
Jul 18, 2009·Biochimica Et Biophysica Acta·Carmelo BernabeuMiguel Quintanilla
Aug 25, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas du BoisJalid Sehouli
Jun 15, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Don S DizonRichard T Penson
Aug 5, 2011·Drugs·R Wendel Naumann, Robert L Coleman
Feb 22, 2012·Clinical Obstetrics and Gynecology·Leigh G SeamonLarry J Copeland
Jun 23, 2018·Clinical & Experimental Metastasis·John K ChanRobert L Coleman
Sep 1, 2010·Experimental and Therapeutic Medicine·Ryuma MatsumotoHiroshi Ishikawa
Jul 22, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Saranya ChanpanitkitchotSunamchok Srijaipracharoen
Aug 20, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jonathan A LedermannJohn A Hartley
Mar 7, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T BaertJ A Ledermann
Aug 10, 2021·ACS Chemical Neuroscience·Alan UmfressJames A Bibb

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.